About Moleculin Biotech, Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
Market Cap
$0.01B
Employees
18
Listed Since
June 2, 2016
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.moleculin.comPhone
713-300-5160
Headquarters
5300 MEMORIAL DRIVE
HOUSTON, TX 77007
CIK
0001659617